Analytical Data
-
Gene name
Oncostatin M/OSM
- Application
-
Alternative Names
Osm; Oncostatin-M; OSM
-
Species
Rat
-
Source
Yeast
-
Tag
N- His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q65Z15
-
Expression Region
26-208aa
-
Molecular Weight
22.6 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
Oncostatin M (OSM) is a member of the interleukin-6 (IL-6) cytokine family, playing a crucial role in various physiological and pathological processes, including inflammation, tissue repair, and tumor progression. OSM is produced by a variety of cell types, including T cells, monocytes, and synovial fibroblasts, and exerts its effects by signaling through the glycoprotein 130 receptor complex, which is shared with other cytokines like IL-6 and leukemia inhibitory factor (LIF). Research demonstrates that OSM is involved in bone metabolism, promoting osteoblast differentiation and inhibiting osteoclastogenesis, thus influencing conditions like osteoporosis and metastatic bone disease. Moreover, OSM has been implicated in the pathogenesis of various diseases, including cancer, rheumatoid arthritis, and cardiovascular disorders, making it a potential therapeutic target. The development of recombinant OSM proteins has facilitated detailed studies of its biological functions and therapeutic applications, fostering a greater understanding of its role in disease modulation. Advances in recombinant DNA technology have also enabled the production of OSM with improved stability and biological activity, paving the way for innovative treatments based on this cytokine. Thus, ongoing research on OSM and its recombinant forms is vital for elucidating their therapeutic potential in targeting inflammation and tumorigenesis, highlighting the importance of this cytokine in both research and clinical settings.
